Teceleukin

DB15389InvestigationalProtein Based Therapies

Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).

Mechanism: Pharmacologically active on Interleukin-2 receptor
Curator reviewed
Code names: RO-236019

Resolves to

Compound

UNIIH5ZRB188EICAS136279-32-8

What you can answer from here — as of September 27, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which companies are running trials of Teceleukin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account